Akebia Therapeutics (AKBA) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
PepGen (PEPG) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 46.8% versus a loss of 77.1%. Akebia Therapeutics is the larger company by market cap ($185.7 million vs $179.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | PEPG |
|---|---|---|
| Share price | $0.67 | $2.60 |
| Market cap | $185.66M | $179.84M |
| 1-day change | -3.67% | +2.77% |
| YTD return | -58.39% | -60.06% |
| 1-year return | -77.13% | -46.83% |
| 5-year return | -76.98% | — |
| EPS (TTM) | $-0.12 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | — |
| Revenue growth (YoY) | +47.46% | — |
| Net income (latest FY) | $-5.34M | $-89.66M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | — |
| Net margin | -2.26% | — |
| 52-week high | $3.20 | $7.80 |
| 52-week low | $0.6659 | $1.31 |
| Distance from 52-week high | -79.06% | -66.67% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +485.07% | +291.92% |
| Average volume | 6.70M | 864.38K |
| Shares outstanding | 277.11M | 69.17M |
| Employees | 194 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed AKBA by 30.3 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
AKBA vs PEPG FAQ
Which is bigger, Akebia Therapeutics or PepGen?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $185.66M compared with $179.84M for PepGen (PEPG).
Which stock has performed better over the past year, AKBA or PEPG?
PEPG returned -46.83% over the past 12 months, compared with -77.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.